Monitoring of glycation, oxidative stress and inflammation in relation to the occurrence of vascular complications in patients with type 2 diabetes mellitus

Physiological Research

Volumn 63, Issue 3, 2014, Pages 297-309

  Jakuš, Vladimír ^a   Sandorova E ^a   Kalninova J ^a   Krahulec, B ^b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

Author keywords

Advanced glycation; Diabetic complications; Inflammation; Oxidative stress; Type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; LIPID PEROXIDE;

AGED; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETIC ANGIOPATHIES; FEMALE; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS;

ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERLEUKIN-6; LIPID PEROXIDES; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 84904210719     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. ABOU SEIF MA, YOUSSEF AA: Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 346: 161-170, 2004.
2. AL-SHABRAWEY M, SMITH S: Prediction of diabetic retinopathy: role of oxidative stress and relevance of apoptotic biomarkers. EPMA J 1: 56-72, 2010.
3. ARONSON D: Hyperglycemia and pathobiology of diabetic complications. Adv Cardiol 45: 1-16. 2008.
4. BANDEIRA SM, FONSECA LJS, GUEDES GS, RABELO LA, GOULART MOF, VASCONCELOS SML: Oxidative stress as an underlying contributor in the development of chronic complications in diabetes mellitus. Int J Mol Sci 14: 3265-3284, 2013.
5. BANSAL S, CHAWLA D, SIDDARTH M, BANERJEE BD, MADHU SV, TRIPATHI AK: A study on serum advanced glycation end products and its association with oxidative stress and paraoxonase activity in type 2 diabetic patients with vascular complications. Clin Biochem 46: 109-114, 2013.
6. BARBARROJA N, LOPEZ-PEDRERA C, GARRIDO-SANCHEZ L, MAYAS MD, OLIVA-OLIVERA W, BERNAL-LOPEZ MR, EL BEKAY R, TINAHONES FJ: Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One 7: e48155, 2012.
7. BASTOS AS, GRAVES DT, LOUREIRO AP, ROSSA JúNIOR C, ABDALLA DS, FAULIN T DO E, OLSEN CâMARA N, ANDRIANKAJA OM, ORRICO SR: Lipid peroxidation is associated with the severity of periodontal disease and local inflammatory markers in patients with type 2 diabetes. J Clin Endocrinol Metab 97: E1353-E1362, 2012.
8. BIGAGLI E, RAIMONDI L, MANNUCCI E, COLOMBI C, BARDINI G, ROTELLA CM, LODOVICI M: Lipid and protein oxidation products, antioxidant status and vascular complications in poorly controlled type 2 diabetes. BJDVD 12: 33-39, 2012.
9. CALDER PC, AHLUWALIA N, BROUNS F, BUETLER T, CLEMENT K, CUNNINGHAM K, ESPOSITO K, JöNSSON LS, KOLB H, LANSINK M, MARCOS A, MARGIORIS A, MATUSHESKI N, NORDMANN H, O'BRIEN J, PUGLIESE G, RIZKALLA S, SCHALKWIJK C, TUOMILEHTO J, WäRNBERG J, WATZL B, WINKLHOFER-ROOB BM: Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 106: 5-78, 2011.
10. CARMAN TL, FERNANDEZ BB Jr: A primary care approach to the patient with claudication. Am Fam Physician 61: 1027-1032, 2000.
11. CHEN M, CURTIS TM, STITT AW: Advanced glycation end products and diabetic retinopathy. Curr Med Chem 20: 3234-3240, 2013.
12. CHILELLI NC, BURLINA S, LAPOLLA A: AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: A "glycoxidation-centric" point of view. Nutr Metab Cardiovasc Dis 23: 913-919, 2013.
13. CHITTAR HS, NIHALANI KD, VARTHAKAVI PK, UDIPI AS: Lipid peroxide levels in diabetics with micro-and macro-angiopathies. J Nutr Biochem 5: 442-445, 1994.
14. DE LA MAZA MP, GARRIDO F, ESCALANTE N, LEIVA L, BARRERA G, SCHNITZLER S, ZANOLLI M, VERDAGUER J, HIRSCH S, JARA N, BUNOUT D: Fluorescent advanced glycation end-products (ages) detected by spectro-photofluorimetry, as a screening tool to detect diabetic microvascular complications. JDM 2: 221-226, 2012.
15. DE REKENEIRE N, PEILA R, DING J, COLBERT LH, VISSER M, SHORR RI, KRITCHEVSKY SB, KULLER LH, STROTMEYER ES, SCHWARTZ AV, VELLAS B, HARRIS TB: Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 29: 1902-1908, 2006.
16. EL-SAADANI M, ESTERBAUER H, EL-SAYED M, GOHER M, NASSAR AY, JüRGENS G: A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 30: 627-630, 1989.
17. ESPOSITO K, NAPPO F, MARFELLA R, GIUGLIANO G, GIUGLIANO F, CIOTOLA M, QUAGLIARO L, CERIELLO A, GIUGLIANO D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067-2072, 2002.
18. GALASSETTI PR, IWANAGA K, PONTELLO AM, YALDIVAR FP, FLORES RL, LARSON JK: Effect of prior hyperglycemia on IL-6 responses to exercise in children with type 1 diabetes. Am J Physiol 290: E833-E839, 2006.
19. GARCIA C, FEVE B, FERRé P, HALIMI S, BAIZRI H, BORDIER L, GUIU G, DUPUY O, BAUDUCEAU B, MAYAUDON H: Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab 36: 327-338, 2010.
20. GARCIA SC, MORETTO MB, MORESCO RN: Plasma malondialdehyde levels and risk factors for the development of chronic complications in type 2 diabetic patients on insulin therapy. Clin Laboratory 58: 973-978, 2012.
21. GIACCO F, BROWNLEE M: Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
22. GRADINARU D, BORSA C, IONESCU C, MARGINA D: Advanced oxidative and glycoxidative protein damage markers in the elderly with type 2 diabetes. J Proteomics 92: 313-322, 2013.
23. HADWAN HM, ALTAEE AH, ZAIDAN HK: The levels of protein oxidation and lipid peroxidation in sera of obese men. J Babylon University 19: 105-110, 2011.
24. HAYASHI T, HIRANO T, YAMAMOTO T, ITO Y, ADACHI M: Intensive insulin therapy reduces small dense lowdensity lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies. Metabol Clin Exper 55: 879-884, 2006.
25. HEGAB Z, GIBBONS S, NEYSES L, MAMAS MA: Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4: 90-102, 2012.
26. HENLE T, DEPPISCH R, BECK W, HERGESELL O, HäNSCH GM, RITZ E: Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14: 1968-1975, 1999.
27. HIGGINS T: HbA1c for screening and diagnosis of diabetes mellitus. Endocrine 43: 266-273, 2013.
28. JAKUS V, RIETBROCK N: Advanced glycation end-products and the progress of diabetic vascular complications. Phys Res 53: 131-142, 2004.
29. JEFFCOATE WJ, GAME F, CAVANAGH PR: The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 336: 2058-2061, 2006.
30. KAEFER M, DE CALVALHO JAM, PIVA SJ, DA SILVA DB, BECKER AM, SANGOI MB, ALMEIDA TC, HERMES CL, COELHO AC, TONELLO R, MOREIRA APL, GARCIA SC, MORETTO MB, MORESCO RN: Plasma malondialdehyde levels and risk factors for the development of chronic complications in type 2 diabetic patients on insulin therapy. Clin Laboratory 58: 973-978, 2012.
31. KALOUSOVá M, ZIMA T, TESAR V, STíPEK S: New markers of advanced damage caused by oxidative and carbonyl stress (in Czech). Sb lek 102: 465-472, 2001.
32. KALOUSOVá M, ŠKRHA J, ZIMA T: Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 51: 597-604, 2002.
33. KANEDA H, TAGUCHI J, OGASAWARA K: Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 162: 221-225, 2002.
34. KERKENI M, SAIDI A, BOUZIDI H, LETAIEF A, BEN YAHIA S, HAMMAMI M: Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res 10: 239-245, 2012.
35. KHAN TH, FAROOQUI FA, NIAZI K: Critical review of the ankle brachial index. Curr Cardiol Rev 4: 101-106, 2008.
36. KILHOVD BK, BERG TJ, BIRKELAND KI, THORSBY P, HANSSEN KF: Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diab Care 22: 1543-1548, 1999.
37. KING GL: The role of inflammatory cytokines in diabetes and its complications. J Periodontol 79: 1527-1534, 2008.
38. KIUCHI K, NEJIMA J, TAKANO T, OHTA M, HASHIMOTO H: Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85: 87-91, 2001.
39. LITTLE JA: Comparison of curve fitting models for ligand binding assays. Chromatographia 59: S177-S181, 2004.
40. MILLER AD, NONAKA S, JAKUŠ J: Modulation of vomiting by the medullary midline. Brain Res 737: 51-58, 1996.
41. MOCAN MC, KADAYIFCILAR S, ELDEM B: Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic nephropathy. Can J Ophtalmol 41: 747-752, 2006.
42. MOORADIAN AD: Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 5: 150-159, 2009.
43. MORA C, NAVARRO JF: Inflammation and diabetic nephropathy. Curr Diabetes Rep 6: 463-468, 2006.
44. MOTAWI TM, ABOU-SEIF MA, BADER AM, MAHMOUD MO: Effect of glycemic control on soluble RAGE and oxidative stress in type 2 diabetic patients. BMC Endocr Disord 13: 32, 2013.
45. MüLLER S, MARTIN S, KOENIG W, HANIFI-MOGHADDAM P, RATHMANN W, HAASTERT B, GIANI G, ILLIG T, THORAND B, KOLB H: Impaired glucose tolerance is associated with increased serum concentrations of interleukin-6 and co-regulated acute-phase proteins but not TNF-αor its receptors. Diabetologia 45: 805-812, 2002.
46. MüNCH G, KEIS R, WESSELS A, RIEDERER P, BAHNER U, HEIDLAND A, NIWA T, LEMKE HD, SCHINZEL R: Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 35: 669-677, 1997.
47. NAVALE AM, PARANJAPE AN: Role of inflammation in development of diabetic complications and commonly used inflammatory markers with respect to diabetic complications. Int J Pharm Sci 5: 1-5, 2013.
48. NEGRE-SALVAYRE A, SALVAYRE R, AUGE N, PAMPLONA R, PORTERO-OTIN M: Hyperglycemia and glycation in diabetic complications. Antioxid Redox Signal 11: 3071-3109, 2009.
49. NGUYEN DV, SHAW LC, GRANT MB: Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne) 21: 1-7, 2012.
50. NICE CLINICAL GUIDELINES, NO. 73: Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. The National Collaborating Centre for Chronic Conditions, Royal College of Physicians (UK), London, 2008, p. 39.
51. NIEMEIJER-KANTERS SD, BANGA JD, ERKELENS DW: Lipid-lowering therapy in diabetes mellitus. Neth J Med 58: 214-222, 2001.
52. NOLAN CJ, DAMM P, PRENTKI M: Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 378: 169-181, 2011.
53. PANENI F, BECKMAN JA, CREAGER MA, COSENTINO F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 34: 2436-2446, 2013.
54. PEDICINO D, LIUZZO G, TROTTA F, GIGLIO AF, GIUBILATO S, MARTINI F, ZACCARDI F, SCAVONE G, PREVITERO M, MASSARO G, CIALDELLA P, CARDILLO MT, PITOCCO D, GHIRLANDA G, CREA F: Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J Diabetes Res 2013: 184258, 2013.
55. PENNO G, SOLINI A, ZOPPINI G, ORSI E, FONDELLI C, ZERBINI G, MORANO S, CAVALOT F, LAMACCHIA O, TREVISAN R, VEDOVATO M, PUGLIESE G; RENAL INSUFFICIENCY AND CARDIOVASCULAR EVENTS (RIACE) STUDY GROUP: Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc Diabetol 12: 1-13, 2013.
56. PIARULLI F, SARTORE G, LAPOLLA A: Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update. Acta Diabetol 50: 101-110, 2013.
57. PICKUP JC, MATTOCK MB, CHUSNEY GD, BURT D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292, 1997.
58. PIWOWAR, A., KNAPIK-KORDECKA, M., WARWAS, M: AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 77: 188-192, 2007.
59. RáCZ O, KUZMOVá D, LEPEJOVá K, DOMBROVSKỲ P: HbA1c-endless story (in Slovak)? Labor Aktuell 1: 24-28, 2012.
60. SáNCHEZ-QUESADA JL, VINAGRE I, DE JUAN-FRANCO E, SáNCHEZ-HERNáNDEZ J, BLANCO-VACA F, ORDóŇEZ-LLANOS J, PéREZ A: Effect of improving glycemic control in patients with type 2 diabetes mellitus on low-density lipoprotein size, electronegative low-density lipoprotein and lipoprotein-associated phospholipase A2 distribution. Am J Cardiol 110: 67-71, 2012.
61. SHI XY, HOU FF, NIU HX, WANG GB, XIE D, GUO ZJ, ZHOU ZM, YANG F, TIAN JW, ZHANG X: Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 149: 1829-1839, 2008.
62. SINGH R, KAUR N, KISHORE L, KUMAR GUPTA G: Management of diabetic complications: a chemical constituents based approach. J Ethnopharmacol 150: 51-70, 2013.
63. SUMEGOVá K, BLAŽíČEK P, WACZULíKOVá I, ŽITŇANOVá I, ĎURAČKOVá Z: Activity of paraoxonase 1 (PON1) and its relationship to markers of lipoprotein oxidation in healthy Slovaks. Acta Biochim 53: 783-787, 2006.
64. THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD) GROUP: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559, 2008.
65. TULADHAR ET, SHARMA VK, SIGDEL M, SHRESTHA L: Type 2 diabetes mellitus with early phase acute inflammatory protein on serum protein electrophoresis. J Patology Nepal 2: 212-214, 2012.
66. TUNES RS, FOSS-FREITAS MC, ROCHA NOGUEIRA-FILHO GDA R: Impact of periodontitis on the diabetesrelated inflammatory status. J Can Dent Assoc 76: 1-7, 2010.
67. UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998.
68. VAN DEN OEVER IA, RATERMAN HG, NURMOHAMED MT, SIMSEK S: Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010: 792393, 2010.
69. VAVERKOVá H: Dyslipoproteinemia and diabetes mellitus (in Czech). Vnitr Lek 46: 532-538, 2000.
70. VIGNALI DA: Multiplexed particle-based flow cytometric assays. J Immunol Methods 243: 243-255, 2000.
71. VIJAYARAGHAVAN K: Treatment of dyslipidemia in patients with type 2 diabetes. Lipids Health Dis 9: 144, 2010.
72. VLASSARA H, URIBARRI J, CAI W, GOODMAN S, PYZIK R, POST J, GROSJEAN F, WOODWARD M, STRIKER GE: Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease: Clin J Am Soc Nephrol 7: 934-942, 2012.
73. WADHAM C, PARKER A, WANG L, XIA P: High glucose attenuates protein S-nitrosylation in endothelial cells. Role of oxidative stress. Diabetes 11: 2715-2721, 2007.
74. WANG X, BAO W, LIU J, OUYANG YY, WANG D, RONG S, XIAO X, SHAN ZL, ZHANG Y, YAO P, LIU LG: Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36: 166-175, 2013.
75. WELLEN KE, HOTAMISHIGIL GS: Inflammation, stress and diabetes. J Clin Invest 115: 1111-1119, 2005.
76. WILLIAMS MD, NADLER JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7: 242-248, 2007.
77. WITKO-SARSAT V, FRIEDLANDER M, CAPEILLÈRE-BLANDIN C, NGUYEN-KHOA T, NGUYEN AT, ZINGRAFF J, JUNGERS P, DESCAMPS-LATSCHA B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313, 1996.
78. WU W, WANG M, SUN Z, WANG X, MIAO J, ZHENG Z: The predictive value of TNF-alfa and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol 49: 3-7, 2012.
79. YADAV UC, RAMANA KV: Regulation of NF-κB-induced inflammatory signaling by lipid peroxidation-derived aldehydes. Oxid Med Cell Longev 2013: 690545, 2013.
80. YAMAMOTO Y, YAMAMOTO H: RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Front Endocrinol (Lausanne) 4: 105, 2013.
81. YAN SF, RAMASAMY R, SCHMIDT AM: Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4: 285-293, 2008.
82. ZOUNGAS S, CHALMERS J, NINOMIYA T, LI Q, COOPER ME, COLAGIURI S, FULCHER G, DE GALAN BE, HARRAP S, HAMET P, HELLER S, MACMAHON S, MARRE M, POULTER N, TRAVERT F, PATEL A, NEAL B, WOODWARD M; ADVANCE COLLABORATIVE GROUP: Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55: 636-643, 2012.
83. ZOZULINSKA D, WIERUSZ-WYSOCKA B: Hyperglycaemia and inflammation are culprits of late diabetic complications. Arch Med Sci 1, 2: 115-118, 2005.